Plasmin is inhibited in vitro by several plasma protease inhibitors including a2-macroglobulin (1-3), al-antitrypsin (1, 4, 5), Ci inactivator (6, 7), and antithrombin-heparin cofactor (8). When these inhibitors are compared in purified systems, a2-macroglobulin appears to be the dominant inhibitor, i. 2 It is also an important inhibitor in vivo because when plasminogen activators are infused, plasmin-a2-macroglobulin complexes have been identified (9). Nevertheless, neither the role of plasma protease inhibitors in modulating intravascular proteolytic events is established, nor is it clear whether the entire spectrum of possible inhibitors has been fully defined.
FIG. 1.
Interaction ofplasmin with a2-plasmin inhibitor. Plasmin (P, 2.5 ~g), gel a, and a2-plasmin inhibitor (a2-PI; 2.0 pg), gel b, were incubated together, gel c, for 2 min at 37°C. After incubation, these mixtures were analyzed in the absence of reduction, by electrophoresis on 5% SDS-acrylamide gels. The anode is toward the bottom of the figure. The location of the inhibitor-plasmin complex is in~iicated (a2PI-P Cx).
urokinase/mg zymogen. Conversion to plasmin was documented by sodium dodecyl sulfate (SDS) 3 gel electrophoretic analysis of reduced samples of the plasminogen-urokinase incubation mixture which demonstrated complete conversion of the plasminogen band to the heavy and light chain of plasmin. Active site titration using p-nitrophenyl p'-guanidinobenzoate hydrochloride (p-NPGB) was performed as described by Chase and Shaw (15) .
Human a2-Macroglobulin. Human a2-macroglobulin was prepared as previously described (16) . The final product migrated as a single protein band aRer reduction as analyzed by SDSacrylamide gel electrophoresis. Concentrations of a2-macroglobulin were established by radial immunodiffusion (Immuno Plate, Hyland Div. Travenol Laboratories, Inc., Costa Mesa, Calif.).
Human c~2-Plasmin Inhibitor. Human a2-plasmin inhibitor was isolated from outdated blood bank plasma as described by Moroi and Aoki (10) . Upon cellulose acetate electrophoresis, the final preparation demonstrated one band with a2-mobility. Upon SDS-gel electrophoresis, the material displayed a major band with an apparent M r = 67,000, consistent with that obtained by Moroi. A minor contaminant, Mr = 64,000, probably similar to that reported by Moroi, was also apparent (Fig. 1, gel b) . Using specific antibodies and double-diffusion analysis, no detectable a~-macroglobulin, Ci inactivator, a~-antitrypsin, antithrombin-heparin cofactor, inter-a-trypsin inhibitor, or chymotrypsin inhibitor were identified in the a2-plasmin inhibitor preparation.
After incubation of az-plasmin inhibitor with plasmin, SDS-gel electrophoretic analysis of the unreduced mixture demonstrated a loss of the protein bands in the a2-plasmin inhibitor and plasmin positions, and a new higher molecular weight band was identified (Fig. 1, gel c) . The apparent Mr of this band was 142,000, consistent with the formation of a complex between plasmin (Mr = 75,000) and a2-plasmin inhibitor. The lower molecular weight band in Fig. I , gels a and c, was a component of the urokinase preparation added to activate plasminogen.
The concentration of functionally active plasmin inhibitor in the final a2-plasmin inhibitor preparation was obtained by titration of a known concentration of plasmin with the inhibitor similar to the method described by Mfillertz and Clemmensen (17) . The inhibition of plasmin was found to be linearly related to the volume of inhibitor added to the incubation mixture containing plasmin and the substrate H-v-valyl-leucyl-lysine-p-nitroanilide. The concentration of active inhibitor was 101 /~g/ml.
SDS-Polyacrylamide Gel Electrophoresis (5% gels)
. This was performed according to the method of Weber and Osborn (18) . Samples for analysis were added to an equal volume of a solution containing 10 M urea and 2% SDS, and boiled for 5 min.
3 Abbreviations used in this paper: Mr, molecular weight; p-NPGB, p-nitrophenylp'-guaniXtinobenzoate hydrochloride; SDS, sodium dodecyl sulfate.
Studies of the Binding of l=l-Plasmin to arMacroglabulin and a~-Plasmin Inhibitor. 125I-
Plasmin was prepared by the activation of 125I-plasminogen with urokinase as described above, and the activity was established by active site titration with p-NPGB. The experimental conditions in these binding studies used physiologic concentrations of a~-macroglobulin (3.5 gM [19] ) since it has been found that this inhibitor is less effective in binding plasmin in more dilute systems (unpublished observations). Since the a~-plasmin inhibitor reacts rapidly with plasmin even at 0°C (10), all incubation mixtures containing the inhibitors were equilibrated at 37°C before the addition of plasmin. Plasmin was added to a~-macroglobulin or to mixtures of a~-macroglobulin and increasing concentrations of a~-plasmin inhibitor. The concentrations of a~-plasmin inhibitor used in these studies (0.06-0.75 ttM) were less than those found for normal plasma (1.1 ttM [10] ). The reaction was terminated by the addition of the SDS-urea solution and boiling. After SDS-gel electrophoresis, the gels were sliced into 2-ram segments and counted in a Searle 1185 gamma counter (Searle Analytic Inc., Des Plaines, Ill.).
Amidolytic Assay. Standard plasmin curves were established using the substrate H-D-valylleucyl-lysine-p-nitroanilide (AB Bofors Nobel Division, Molndal, Sweden) using minor modifications of the methods detailed by the manufacturers. A constant concentration of plasmin was added to a constant concentration of a~-macroglobulin or to a mixture of a2-macroglobulin and increasing concentrations of a~-plasmin inhibitor in the concentrations indicated in Table II . The final incubation volume was 1.2 ml and contained 330 gg substrate. After a 15-rain incubation at 37°C, 30% acetic acid (0.3 ml), was added to stop the reaction, and the abserbance was recorded at 410 nm. Residual plasmin activity was established from the linear plasmin standard curves, a2-Macreglobulin was found not to inhibit the amidolytic activity of plasmin since the residual activity of a mixture of a2-macroglobulin and plasmin was similar to the activity expressed by plasmin alone. (20) with bovine serum albumin (Pentex Biochemical, Kankakee, Ill.) as the reference standard.
Protein. Protein was measured by the Lowry procedure

Results
The Interaction of l~sI-Plasrnin with a2-Macroglobulin and a2-Plasrnin Inhibitor as Analyzed by SDS-Acrylamide Gel Electrophoresis.
To define the relative importance of purified a2-macroglobulin and a2-plasmin inhibitor as plasmin inhibitors, the amount of 12SI-plasmin bound to each in incubation mixtures of the two was determined. This proved feasible as preliminary studies established that complexes between radiolabeled plasmin and either inhibitor did not dissociate after electrophoresis in SDS gels. Further, the electrophoretic mobility of the plasmin, a~-macroglobulin complex near the top of the gel I was sufficiently different from that of the plasmin, a2-plasmin inhibitor complex ( Fig. 1) to make it possible to separate these complexes in mixtures ofinhibitors and plasmin. Thus, analysis of incubation mixtures of ~2SI-plasmin, as-macroglobulin, and varying concentrations of a2-plasmin inhibitor by SDS-acrylamide gel electrophoresis demonstrated the quantitative contribution of each in binding plasmin (Table I) .
In the present studies, concentrations of plasmin were selected which were well below the previously established 1 to 1 M binding capacity of a2-macroglobulin. 1 Under these conditions, comparison of the binding of 125I-plasmin to mixtures of the inhibitors at 10 and 120 s of incubation demonstrated that the reactions were complete by 10 s since no shift of radioactivity between inhibitorenzyme complexes was detected. As indicated in Table I , when a constant amount of plasmin (0.28 ftM) was added to a2-macroglobulin (3.5 ftM) and increasing concentrations of a~-plasmin inhibitor (0.06-0.75 ftM), the a2-plasmin inhibitor always bound nearly as much plasmin as it did in the absence of After a 10-s incubation, a solution of SDS and urea was added to terminate the reaction. The mixtures were then analyzed by SDS-acrylamide gel electrophoresis, and 2-mm gel segments were counted in a gamma counter. 5 ftl 12~I-plasmin (0.28 /~M) was incubated with buffer (0/~M ol2-PI) or with varying concentrations of a2-PI as indicated in the table and under the conditions described above. No asmacroglobulin was included in these mixtures. § Percent plasmin bound was calculated as the counts per minute associated with the 12~I-plasmina2-macroglobulin complex or with the ~2SI-plasmin-as-plasmin inhibitor complex divided by the sum of the cpm of these complexes plus the radioactivity of the unbound plasmin. All values are the mean of duplicate determinations.
a2-macroglobulin. This effect was apparent in a2-plasmin inhibitor to ~-macroglobulin molar ratios as small as 0.02. The amount of the radiolabeled plasmin which was identified in complexes with the inhibitors (46%) was in agreement with the results of active site titration of the plasmin preparation used, which demonstrated a 50% activity. For reasons which are poorly understood, in the mixture of enzyme and inhibitor with the lowest concentration of a2-plasmin inhibitor (0.06 IzM), no inhibitorplasmin complex was identified after SDS-gel electrophoresis (three experiments), although binding to this concentration of inhibitor was detectable in the presence of a2-macroglobulin.
In other experiments not shown in Table I , preincubation of a2-macroglobulin (3.5 ftM) with 125I-plasmin for 2 rain at 37°C, followed by the addition of a2-plasmin inhibitor (0.75 ftM) for a similar incubation period, demonstrated that all the active plasmin remained bound to ~2-macroglobulin and none became associated with the a2-plasmin inhibitor. In an experiment reversing the addition sequence in which 125I-plasmin was added to ~2-plasmin inhibitor first followed by addition of a2-macroglobulin, plasmin was identified in the asplasmin inhibitor, plasmin complex, and none became associated with a2-macroglobulin. Thus, we conclude that after initial binding, there is no transfer of enzyme from one inhibitor to the other.
The Binding of Plasmin to arMacroglobulin in the Presence of az-Plasmin Inhibitor as Determined by an Amidolytic Assay.
To test for the binding of unlabeled, native plasmin to a2-macroglobulin in the presence of varying concentrations of a2-plasmin inhibitor, a second technique was utilized. This method of analysis was made possible by the observation that the hydrolytic activity of plasmin against low molecular weight substrates was preserved after complex formation with a2-macroglobulin (3, 21) . We first established that the hydrolysis of the chromogenic synthetic peptide H-v-valyl-L-leucyl-L-lysine-pnitroanilide by plasmin was inhibited completely by a~-plasmin inhibitor, but was not inhibited when plasmin was bound to a~-macroglobulin. Furthermore, we established that a2-plasmin inhibitor caused negligible inhibition of the amidolytic activity of the a2-macroglobulin-plasmin complex. Therefore, when plasmin is added to mixtures of both inhibitors, the amount of enzyme bound to a2-macroglobulin can be quantitated by the preservation of amidolytic activity.
Assays using this substrate confirmed the effectiveness of a2-plasmin inhibitor in competing with a2-macroglobulin for plasmin (Table II) . Increasing concentrations of a2-plasmin inhibitor in a mixture of a constant concentration of plasmin and a~-macroglobulin caused a reduction in the amidolytic activity of the incubation mixture which was proportional to the final concentration of a2-plasmin inhibitor added. Comparison of the plasmin activity of the incubation mixtures containing a~-plasmin inhibitor and plasmin with those mixtures which also included a2-macroglobulin demonstrated no significant differences. Thus, the a2-plasmin inhibitor competed with a2-macroglobulin as effectively for native plasmin as it did for the radiolabeled enzyme.
Discussion
Previous studies from our laboratory have examined the interactions between plasmin and mixtures of purified plasma protease inhibitors in the concentrations found in plasma. In mixtures containing a2-macroglobulin, al-antitrypsin, and Ci inactivator, the a2-macroglobulin was found to bind most of the plasmin which was added.: In a similar analysis, a~-macroglobulin competed effectively for plasmin in the presence of antithrombin-heparin cofactor. 2 The addition of heparin, however, enabled the antithrombin-heparin cofactor to bind slightly more plasmin that did the a2-macroglobulin. Thus, in the competition among plasma inhibitors for plasmin in the absence of heparin, a2-macroglobulin binds plasmin more rapidly than does a~-antitrypsin, Ci inactivator, and antithrombin-heparin cofactor.
Moroi and Aoki (10) have recently isolated a plasma inhibitor of plasmin, termed the a2-plasmin inhibitor, which rapidly formed a complex with plasmin and which completely inhibited the proteolytic and esterolytic activity of the enzyme. This inhibitor appears to be identical to the partially purified, rapidly acting plasmin inhibitor described by Miillertz and Clemmensen (17) . Both Miillertz (22) and Collen (23) have documented that in vitro activation of small amounts of plasminogen in plasma results in the appearance of the as-plasmin inhibitor-plasmin complex, which precedes the formation of the plasmin-a2- macroglobulin complex. These observations suggest that the a2-macroglobulin may function as a plasmin inhibitor after the saturation of the a2-plasmin inhibitor.
In the present study, we have examined directly the ability of a2-plasmin inhibitor to bind plasmin in the presence of a2-macroglobulin. The results of two different methods designed to assess complex formation between plasmin and these inhibitors were entirely comparable and indicated that ~25I-plasmin bound as readily to these inhibitors as did the native enzyme. Comparison of the distribution of radiolabeled plasmin between the two inhibitors at 10 and 120 s of incubation showed an identical binding pattern, indicating that the reactions were rapid, being completed by 10 s. Preincubation of plasmin with one inhibitor followed by the addition of the other established that transfer of the enzyme between the inhibitors did not occur.
The reported plasma concentration of ~2-plasmin inhibitor (1.1 ftM [10] ), and of a2-macroglobulin (3.5/~M [16] ), represents a molar ratio of 0.3. In our binding studies, a2-plasmin inhibitor to a2-macroglobulin molar ratios from 0.01 to 0.21 have been examined. Over this range of a2-plasmin inhibitor concentrations, approximately as much plasmin was bound to the a2-plasmin inhibitor in mixtures which contained a2-macroglobulin as in those which did not. This indicates that when both inhibitors simultaneously compete for plasmin, the a2-plasmin inhibitor binds the enzyme much more rapidly than does the a2-macroglobulin. These data strengthen the concept that the a2-plasmin inhibitor may represent the primary plasmin inhibitor in the circulating blood. Summary a2-Plasmin inhibitor and a2-macroglobulin were allowed to compete for the protease plasmin. The binding of the enzyme to these inhibitors was assessed by two different but comparable methods. The interactions were completed in 10 s of incubation, and transfer of plasmin from one inhibitor to the other did not occur. Almost as much plasmin was bound to a2-plasmin inhibitor in mixtures containing a large molar excess of a2-macroglobulin relative to plasmin or a2-plasmin inhibitor, as was bound in mixtures not containing a2-macroglobulin. These studies demonstrate directly the effectiveness of a2-plasmin inhibitor in binding and inhibiting plasmin in the presence of a2-macroglobulin, and suggest that the a2-plasmin inhibitor may be the major circulating plasmin inhibitor.
